Oregon Health and Science University said this week that it will collaborate with OHSU spinout Najit Technologies and Washington University in St. Louis to develop a vaccine for West Nile virus under a four-year, $7.3 million grant from the National Institute of Allergy and Infectious Diseases.

The partners, using a platform technology owned by OHSU and exclusively licensed to Najit, plan to create an inactivated formulation that remains highly immunogenic but may be safer to administer to immunocompromised patients than existing vaccines.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.